Evidence map›Paper›PMID 39639028›Full record

ArticleTranslational psychiatry2024

Prefrontal electrophysiological biomarkers and mechanism-based drug effects in a rat model of alcohol addiction.

Bettina Habelt, Dzmitry Afanasenkau, Cindy Schwarz, Kevin Domanegg, Martin Kuchar, Carsten Werner, Ivan R Minev, Rainer Spanagel, Marcus W Meinhardt, Nadine Bernhardt

Abstract read
In one paragraph

Article in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bettina HabeltDepartment of Psychiatry and Psychotherapy, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Dzmitry AfanasenkauBiotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering (CMCB), Technische Universität Dresden, Dresden, Germany.
Cindy SchwarzDepartment of Psychiatry and Psychotherapy, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Kevin DomaneggInstitute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Martin KucharForensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic.
Carsten WernerLeibniz Institute of Polymer Research Dresden, Dresden, Germany.
Ivan R MinevLeibniz Institute of Polymer Research Dresden, Dresden, Germany.
Rainer SpanagelInstitute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.ORCID 0000-0003-2151-4521
Marcus W Meinhardt *Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. marcus.meinhardt@zi-mannheim.de.ORCID 0000-0002-5103-0731
Nadine Bernhardt *Department of Psychiatry and Psychotherapy, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. nadine.bernhardt@uniklinikum-dresden.de.ORCID 0000-0002-3188-8431

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01EW1908Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 01ZX1909ADeutsche Forschungsgemeinschaft (German Research Foundation) 402170461Deutsche Forschungsgemeinschaft (German Research Foundation) 521379614Deutsche Forschungsgemeinschaft (German Research Foundation) ME 5279/3-1EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 804005Volkswagen Foundation (VolkswagenStiftung) 91690
6 · The paper itself

Abstract

Patients with alcohol use disorder (AUD) who seek treatment show highly variable outcomes. A precision medicine approach with biomarkers responsive to new treatments is warranted to overcome this limitation. Promising biomarkers relate to prefrontal control mechanisms that are severely disturbed in AUD. This results in reduced inhibitory control of compulsive behavior and, eventually, relapse. We reasoned here that prefrontal dysfunction, which underlies vulnerability to relapse, is evidenced by altered neuroelectric signatures and should be restored by pharmacological interventions that specifically target prefrontal dysfunction. To test this, we applied our recently developed biocompatible neuroprosthesis to measure prefrontal neural function in a well-established rat model of alcohol addiction and relapse. We monitored neural oscillations and event-related potentials in awake alcohol-dependent rats during abstinence and following treatment with psilocybin or LY379268, agonists of the serotonin 2A receptor (5-HT

Indexed as

AlcoholismBridged Bicyclo Compounds, HeterocyclicDisease Models, AnimalPrefrontal CortexPsilocybinAmino AcidsAnimalsBiomarkersEvoked PotentialsMaleRatsReceptors, Metabotropic GlutamateAmino AcidsBiomarkersBridged Bicyclo Compounds, HeterocyclicLY 379268metabotropic glutamate receptor 2PsilocybinReceptors, Metabotropic Glutamate

Identifiers

PMID39639028
PMCPMC11621398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.